Advertisement


Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)

2016 ESMO Congress

Advertisement

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)



Related Videos

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Abstract LBA43)

Lung Cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)

Lung Cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)

Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)

Breast Cancer

Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin (Spanish Language Version)

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)

Lung Cancer

Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–small cell lung cancer previously treated with chemotherapy and crizotinib.

Advertisement

Advertisement




Advertisement